Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based PMV Pharmaceuticals has entered into a licensing agreement and drug discovery collaboration with Chiromics.
Subscribe to our email newsletter
Under the deal, PMV Pharma will have a non-exclusive license to use Chiromics’ chemical compound library and a screening collaboration to discover and optimize new small molecules against multiple PMV oncology and infectious disease therapeutic targets.
PMV Pharma develops p53 targeted small molecule drugs for the treatment of cancer and infectious disease.
p53 is the most commonly mutated protein in human cancers with more than half of all tumors containing mutant p53.
The company said that it is also a key cellular defense against viral infection and is known to suppress the replication of numerous viruses.
Chiromics’ compound collections are assembled using its core chemical technology referred to as cascade catalysis, which helps in the creation of ‘accessible complexity’ – a diverse collection of molecules that is more complex than, and differentiated from, currently existing small molecule collections.
PMV Pharmaceuticals president and CEO David Mack said the company is happy to use Chiromics’ proprietary technology and libraries together with our novel p53 platform and insights.
"The result of this powerful combination will be the rapid discovery of a portfolio of important new potential oncology and infectious disease therapeutics," Mack said.
Chiromics founder David MacMillan said PMV Pharma has assembled a first class team with proven expertise in understanding the biology of p53.
"Our chemistry platform together with PMV’s deep knowledge of the p53 network has the potential to achieve unprecedented results," MacMillan said.